Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 3Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Hepatoblastoma 1

Interventions

Fluorouracil 74Leucovorin 48Oxaliplatin 44Cisplatin 40Capecitabine 39Gemcitabine 37Radiotherapy 30Irinotecan 28Cetuximab 21Paclitaxel 15Bevacizumab 12Docetaxel 10Taxes 9durvalumab 8dehydroftorafur 8Surgical Procedures, Operative 8Mitomycin 8Specimen Handling 7Platinum 7Folfox protocol 7Carboplatin 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7S 1 (combination) 6Panitumumab 6Watchful Waiting 5Imatinib Mesylate 5Gene Expression Profiling 5Epirubicin 5tremelimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × imetelstat × Gastrointestinal × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡